Pharmacodynamics of thalidomide in the thalidomide group
| Pharmacokinetic parameters | T1 | T2 | T3 |
|---|---|---|---|
| Age, years | 6 | 25 | 1 |
| AUCt (hr·ng/ml) | 11,238.10 | 22,824.50 | 14,493.20 |
| AUC∞(hr·ng/ml) | 11,470.90 | 24,431.50 | 14,920.90 |
| Cmax (ng/ml) | 1,232.20 | 2,454.70 | 2,711.90 |
| tmax (h) | 4.00 | 3.87 | 1.88 |
| t1/2 (h) | 4.06 | 5.65 | 4.87 |
| Pharmacokinetic parameters | T1 | T2 | T3 |
|---|---|---|---|
| Age, years | 6 | 25 | 1 |
| AUCt (hr·ng/ml) | 11,238.10 | 22,824.50 | 14,493.20 |
| AUC∞(hr·ng/ml) | 11,470.90 | 24,431.50 | 14,920.90 |
| Cmax (ng/ml) | 1,232.20 | 2,454.70 | 2,711.90 |
| tmax (h) | 4.00 | 3.87 | 1.88 |
| t1/2 (h) | 4.06 | 5.65 | 4.87 |
AUCt, area under the plasma concentration–time curve from time zero to the last measured time point; AUC∞, area under the plasma concentration–time curve from time zero extrapolated to infinity; Cmax, maximum plasma concentration; tmax, time to maximum plasma concentration; t1/2, elimination half-life.
Sharing content requires targeting cookies to be enabled. Please update your cookie preferences to use this feature.